CAS：367-93-1| The Application of IPTG in Biopharmaceutical Technology

Product Name：IPTG
CAS：367-93-1
Molecular Formula：C9H18O5S
Article No.：Y0014
Structural Formula：

Product Introduction
IPTG is a highly potent inducer that is widely used in laboratories due to its stability during the induction process, as it is not metabolized by bacteria. IPTG is commonly used as an inducer in  biopharmaceuticals and enzyme catalysis technology.
Application of IPTG
Vaccination is the most effective public intervention to prevent novel coronavirus infection. At present, the global research and development routes for vaccines mainly include the following: viral vaccines represented by inactivated vaccines and attenuated live vaccines; Recombinant subunit vaccines using S protein, RBD, viral like particles or peptides as antigens; DNA or RNA based nucleic acid vaccines, as well as vector vaccines including non replicative and replicative types. With the prevalence of novel coronavirus, more and more mutants have been found. It is crucial to develop safer and more effective SARS-CoV-2 vaccines in response to the continuous mutation of the SARS-CoV-2 virus. Therefore, CN117924437A patent has developed a new type of recombinant subunit antigen of novel coronavirus and its preparation method and application. The specific preparation method is as follows:
(1) Assemble the nucleotide sequence of HR1 910-1011-L6-HR2P as the target gene with the pET30a plasmid, and then transfer it into Rosetta competent cells to obtain the expressing bacteria containing the target gene;
(2) The expressed bacteria containing the target gene were broken after induction by IPTG, and the required recombinant protein of novel coronavirus was obtained by chromatography.
The induction process of IPTG is as follows: after shaking the expression bacteria containing the target gene in LB containing Kana for 4-5 hours, adding IPTG at a rate of 500μL of bacterial solution: 1mM IPTG, and continuing shaking for 3-4 hours, then extracting the bacterial solution and centrifuging to obtain the induced bacterial body.
The novel coronavirus recombinant protein provided by the patented technology is highly conservative against coronavirus and COVID-19 mutants, and contains rich effective T cell epitopes with good immunogenicity, which can stimulate the body to produce antigen specific antibodies and cellular immune responses. The recombinant protein of the invention can use the prokaryotic expression system as the expression vector, and has the advantages of high yield, low production cost, high protein purity and similar physiological status, which is suitable for large-scale preparation of COVID-19 vaccine.

References
CN117924437A A novel recombinant subunit antigen of novel coronavirus and its preparation and application.